var data={"title":"Factor IX, recombinant human: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Factor IX, recombinant human: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7769?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=factor-ix-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor IX, recombinant human: Drug information&quot;</a> and <a href=\"topic.htm?path=factor-ix-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">see &quot;Factor IX, recombinant human: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255881\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>BeneFIX;</li>\n      <li>Ixinity;</li>\n      <li>Rixubis</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255882\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>BeneFix</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F989980\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antihemophilic Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324145\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>NOTE:</b> Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b>  IV: Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleed, and clinical situation of patient. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Formula for units required to raise blood level: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">BeneFIX:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Number of Factor IX Units Required = body weight (in kg) x desired factor IX level increase (% or units/dL) x 1.4 units/kg per units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">For example, for a 100% level in a 3 kg patient who has an actual level of 20%: Number of Factor IX Units needed = 3 kg x 80% x 1.4 units/kg per units/dL = 336 units </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Intermittent IV: Desired factor IX level, dosing interval and duration based on hemorrhage type: </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor hemorrhage (uncomplicated joint hemorrhage, superficial muscle, or soft tissue): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor IX levels (% or units/dL): 20 to 30 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: 1 to 2 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Moderate hemorrhage (intramuscular or soft tissue with dissection, mucous membrane, dental extractions, or hematuria): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor IX levels (% or units/dL): 25 to 50 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: Until bleeding stops and healing begins, ~2 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major hemorrhage (pharynx, retorpharnynx, retroperitoneum, CNS, surgery): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor IX levels (% or units/dL): 50 to 100 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: 7 to 10 days </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F989987\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=factor-ix-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor IX, recombinant human: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>NOTE:</b> Contains <b>only factor IX</b>; therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis). </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Dosage is expressed in units of factor IX activity and must be individualized based on formulation, severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Formula for units required to raise blood level: </i></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants, Children, and Adolescents &lt;15 years: BeneFIX:  Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1.4 units/kg per units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For example, for a 100% level in a 25 kg patient who has an actual level of 20%: Number of factor IX Units needed = 25 kg x 80% x 1.4 units/kg per units/dL = 2,800 units</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Adolescents &ge;15 years: BeneFIX: Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1.3  units/kg per units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">For example, for a 100% level in a 70 kg patient who has an actual level of 20%: Number of factor IX Units needed = 70 kg x 80% x 1.3 units/kg per units/dL = 7,280 units</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Manufacturer's labeling:</i> BeneFIX: Infants, Children, and Adolescents: Intermittent IV: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Desired factor IX level, dosing interval and duration based on hemorrhage type:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Minor hemorrhage (uncomplicated joint hemorrhage, superficial muscle, or soft tissue): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor IX levels (% or units/dL): 20 to 30 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: 1 to 2 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Moderate hemorrhage (intramuscular or soft tissue with dissection, mucous membrane, dental extractions, or hematuria): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor IX levels (% or units/dL): 25 to 50 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: Until bleeding stops and healing begins, ~2 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Major hemorrhage (pharynx, retorpharnynx, retroperitoneum, CNS, surgery): </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired factor IX levels (% or units/dL): 50 to 100 </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Frequency of dosing: Every 12 to 24 hours </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Duration of treatment: 7 to 10 days </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Alternative dosing:</i> <b>Note:</b> The following recommendations reflect general dosing requirements; may vary from those found within prescribing information or practitioner preference: </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Prophylaxis, primary: Infants, Children, and Adolescents: IV: 15 to 30 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Utrecht protocol)] <b>or</b> 25 to 40 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Malm&ouml; protocol)] <b>or</b> 40 to 100 units/kg administered 2 to 3 times weekly (National Hemophilia Foundation, MASAC recommendation 2007); optimum regimen has yet to be defined. </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemorrhage, treatment: <b>Note:</b> Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose. Infants, Children, and Adolescents: IV:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Desired Factor IX Level to Maintain and Duration Based on Site of Hemorrhage/Clinical Situation (when no significant resource constraints exist) [WFH guidelines (Srivastava 2013)]:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Joint: 40 to 60 units/dL for 1 to 2 days, may be longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Superficial muscle (no neurovascular compromise): 40 to 60 units/dL for 2 to 3 days, sometimes longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss: Initial: 60 to 80 units/dL for 1 to 2 days; Maintenance: 30 to 60 units/dL for 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">CNS/head: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Throat and neck: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Gastrointestinal: Initial: 60 to 80 units/dL for 7 to 14 days; Maintenance: 30 units/dL (duration not specified) </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Renal: 40 units/dL for 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Deep laceration: 40 units/dL for 5 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (major): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 60 to 80 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 40 to 60 units/dL for 1 to 3 days; then 30 to 50 units/dL for 4 to 6 days; then 20 to 40 units/dL for 7 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (minor):</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 50 to 80 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 30 to 80 units/dL for 1 to 5 days depending on procedure type </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Control or prevention of bleeding in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> IV: Dosage is expressed in units of factor IX activity; dosing must be individualized based on severity of factor IX deficiency, extent and location of bleeding, and clinical status of patient. Refer to product information for specific manufacturer recommended dosing. Alternatively, the World Federation of Hemophilia (WFH) has recommended general dosing for factor IX products.</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Formula for units required to raise blood level:</i> <b>Note:</b> If patient has severe hemophilia (ie, baseline factor IX level is or presumed to be &lt;1%), then may just use &ldquo;desired factor IX level&rdquo; instead of &ldquo;desired factor IX level increase&rdquo;.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Number of factor IX units required = patient weight (in kg) x desired factor IX level increase (as % or units/dL) x 1.3 units/kg per units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>World Federation of Hemophilia (WFH) Guidelines (Srivastava 2013):</i> <b>Note:</b> The following recommendations may vary from those found within prescribing information or practitioner preference.  </p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Prophylaxis, primary: IV: 15 to 30 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Utrecht protocol)] <b>or</b> 25 to 40 units/kg twice weekly [WFH guidelines (Srivastava 2013) (Malm&#1255; protocol)] <b>or</b> 40 to 100 units/kg 2 or 3 times weekly (National Hemophilia Foundation, MASAC recommendation 2007); however, the optimum regimen has yet to be defined.</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Treatment: Intermittent IV: 2013 World Federation of Hemophilia Treatment Recommendations (When No Significant Resource Constraint Exists): <b>Note:</b> Factor IX level may either be expressed as units/dL or as %. Dosing frequency most commonly corresponds to the half-life of factor IX but should be determined based on an assessment of factor IX levels before the next dose. </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Desired  Factor IX Level to Maintain and Duration Based on Site of Hemorrhage/Clinical Situation:  </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Joint: 40 to 60 units/dL for 1 to 2 days, may be longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Superficial muscle (no neurovascular compromise): 40 to 60 units/dL for 2 to 3 days, sometimes longer if response is inadequate </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Iliopsoas and deep muscle with neurovascular injury, or substantial blood loss: Initial: 60 to 80 units/dL for 1 to 2 days; Maintenance: 30 to 60 units/dL for 3 to 5 days, sometimes longer as secondary prophylaxis during physiotherapy </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">CNS/head: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 21 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Throat and neck: Initial: 60 to 80 units/dL for 1 to 7 days; Maintenance: 30 units/dL for 8 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Gastrointestinal: Initial: 60 to 80 units/dL for 7 to 14 days; Maintenance: 30 units/dL (duration not specified) </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Renal: 40 units/dL for 3 to 5 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Deep laceration: 40 units/dL for 5 to 7 days </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Surgery (major): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 60 to 80 units/dL </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 40 to 60 units/dL for 1 to 3 days; then 30 to 50 units/dL for 4 to 6 days; then 20 to 40 units/dL for 7 to 14 days </p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Surgery (minor): </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Preop: 50 to 80 units/dL</p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Postop: 30 to 80 units/dL for 1 to 5 days depending on procedure type </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Continuous IV infusion: <b>Note:</b> For patients who require prolonged periods of treatment (eg, intracranial hemorrhage or surgery) to avoid peaks and troughs associated with intermittent infusions [Batorova 2002; Poon 2012; Rickard 1995; WFH guidelines (Srivastava 2013)]: Following initial bolus to achieve the desired factor IX level: Initiate 4 to 6 units/kg/hour; adjust dose based on frequent factor assays and calculation of factor IX clearance at steady-state using the following equations: </p>\n    <p style=\"text-indent:-2em;margin-left:12em;\">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour)/(plasma level in units/<b>mL</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">Factor IX clearance (mL/kg/hour) = (current infusion rate in units/kg/hour)/(plasma level in units/mL) </p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/mL) </p>\n    <p style=\"text-indent:-2em;margin-left:14em;\">New infusion rate (units/kg/hour) = (factor IX clearance in mL/kg/hour) x (desired plasma level in units/<b>mL</b>) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Routine prophylaxis to prevent bleeding episodes in patients with factor IX deficiency (hemophilia B or Christmas disease):</b> Rixubis: IV: 40 to 60 units/kg twice weekly; may titrate dose depending upon age, bleeding pattern, and physical activity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242348\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Kit, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">BeneFIX: 250 units, 500 units, 1000 units, 2000 units, 3000 units [contains polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Ixinity: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 1500 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains mouse (murine) and/or hamster protein, polysorbate 80]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Rixubis: 250 units (1 ea); 500 units (1 ea); 1000 units (1 ea); 2000 units (1 ea); 3000 units (1 ea) [contains polysorbate 80]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255883\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">May be product dependent</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25573584\" class=\"block dosfc drugH1Div\"><span class=\"drugH1\">Dosage Forms Considerations</span><p>(For additional information <a href=\"topic.htm?path=factor-ix-recombinant-human-drug-information\" class=\"drug drug_general\">see &quot;Factor IX, recombinant human: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">Strengths expressed with approximate values. Consult individual vial labels for exact potency within each vial.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324139\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Solution should be infused at room temperature. With patients who have had allergic reactions during factor IX infusion, administration of hydrocortisone prior to infusion may be necessary [WFH guidelines (Srivastava 2013)].</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV bolus:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">BeneFIX: Should be infused <b>slowly over several minutes</b>. Rate of administration should be determined by the response and comfort of the patient.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rixubis: Bolus infusion; maximum rate of administration is 10 mL/minute</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">WFH recommendations (Srivastava 2013): Infuse at a rate determined by age: Young children: 100 <b>units</b>/minute; Adults: 3 mL/minute </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Continuous IV infusion: Limited data available in select patients: Infuse as directed. Evidence supporting the use of continuous infusion is primarily with BeneFix (Chowdary 2001). The safety and efficacy of Rixubis and Alprolix administration by continuous infusion has not been established.  </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16256024\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BeneFIX: Store at 2&deg;C to 30&deg;C (36&deg;F to 86&deg;F). Avoid freezing which may damage the diluent syringe. Reconstituted solution should be at room temperature and used within 3 hours of preparation. Do not refrigerate after reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ixinity: Store 250 unit strength at 2&deg;C to 8&deg;C (36&deg;F to 47&deg;F); store 500 unit, 1,000 unit, 1,500 unit, 2,000 unit, and 3,000 unit strength at 2&deg;C to 25&deg;C (36&deg;F to 77&deg;F). Do not freeze. Keep vial in the carton and protect from light. Infuse reconstituted solution immediately or within 3 hours when stored at room temperature. Do not refrigerate after reconstitution.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rixubis: Store at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F); do not freeze. May store at room temperature not to exceed 30&deg;C (86&deg;F) for up to 36 months; do not return to refrigerator. Infuse  at room temperature and within 3 hours of reconstitution; do not refrigerate after reconstitution.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F989981\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BeneFIX: Prevention and control of bleeding in patients with hemophilia B (congenital factor IX deficiency or Christmas disease); perioperative management in patients with hemophilia B [All indications: FDA approved in pediatric patients (age not specified) and adults]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rixubis: Prevention and control of bleeding episodes in patients with hemophilia B (congenital factor IX deficiency or Christmas disease); perioperative management in patients with hemophilia B; routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia B (All indications: FDA approved in adults)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>NOTE:</b> Contains <b>only factor IX</b>. Therefore, <b>NOT INDICATED</b> for replacement therapy of any other clotting factor besides factor IX or for reversal of anticoagulation due to either vitamin K antagonists or other anticoagulants (eg, dabigatran), for hemophilia A patients with factor VIII inhibitors, or for patients in a hemorrhagic state caused by reduced production of liver-dependent coagulation factors (eg, hepatitis, cirrhosis). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255858\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Factor IX may be confused with Factor IX Complex</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16256000\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Chest tightness, flushing, thromboembolic complications, thromboembolism</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Apathy, chills, depression, dizziness, drowsiness, headache, lethargy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Pruritic rash, skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Dysgeusia, nausea, oral paresthesia, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Hemophilia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Immunologic: Antibody development</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Influenza</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Local: Cellulitis at injection site, discomfort at injection site, injection site phlebitis, injection site reaction, pain at injection site</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Limb pain, tremor, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Blurred vision</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Renal infarction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Cough, dyspnea, hypoxia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Anaphylaxis, hypotension, nephrotic syndrome (associated with immune tolerance induction), obstructive uropathy, palpitations, superior vena cava syndrome (neonates)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242351\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Life-threatening, immediate hypersensitivity reactions (including anaphylaxis) to coagulation factor IX, hamster protein, or any component of the formulation; disseminated intravascular coagulation (Rixubis); signs of fibrinolysis (Rixubis).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242343\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antibody formation: The development of factor IX antibodies (or inhibitors) has been reported with factor IX therapy (usually occurs within the first 10 to 20 exposure days); the risk of severe hypersensitivity reactions occurring may be greater in these patients. When clinical response is suboptimal, the patient has reached a specified number of exposure days, or patient is to undergo surgical procedure, screen for inhibitors. Patients with severe hemophilia compared to those with mild or moderate hemophilia are more likely to develop inhibitors (WFH [Srivastava 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity reactions: Hypersensitivity reactions (including anaphylaxis) may occur; risk is highest during the early phases of initial exposure in previously untreated patients, especially those with high-risk gene mutations. Delayed reactions (up to 20 days after infusion) in previously untreated patients may also occur. Due to potential for allergic reactions, the initial ~10 to 20 administrations should be performed under appropriate medical supervision. Hypersensitivity reactions have frequently occurred in close temporal association with the development of factor IX inhibitors; patients experiencing allergic reactions should be evaluated for factor IX inhibitors. If hypersensitivity reactions occur, discontinue immediately; in the case of severe allergic reactions, consider the use of alternative hemostatic measures (WFH [Srivastava 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotic syndrome: Nephrotic syndrome has been reported following attempted immune tolerance induction in hemophilia B patients with factor IX inhibitors and a history of allergic reactions. Safety and efficacy in this situation have not been established.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Thrombotic events: Thromboembolism (eg, pulmonary embolism, venous/arterial thrombosis) may occur. Monitor for early signs of thromboembolism and coagulopathy in patients with hepatic disease, fibrinolysis, peri- and postoperative patients, or patients at risk for thromboembolic events or disseminated intravascular coagulation (DIC). The benefit of treatment should be weighed against the risk of complications in patients with DIC or those at risk for DIC or thromboembolic events. Reports of thrombotic events have also been reported in patients receiving continuous infusion through a central venous catheter, including life-threatening superior vena cava syndrome in critically ill neonates.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with extreme caution in patients with hepatic impairment due to the increased risk of thromboembolic complications.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>\n        <b>Dosage form specific issues:</b></i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hamster protein: May contain trace amounts of Chinese hamster proteins; hypersensitivity to these proteins may develop.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Clinical response: Response to factor IX administration may vary. If bleeding is not controlled with the recommended dose, determine plasma level of factor IX and follow with a sufficient dose to achieve satisfactory clinical response. If plasma levels of factor IX fail to increase as expected or bleeding continues, suspect the presence of an inhibitor; test as appropriate.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27235969\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Use with caution when administering to neonates; the safety and efficacy of continuous infusion administration has not been established; thrombotic events have been reported in patients receiving continuous infusion of recombinant Factor IX through a central venous catheter, including life-threatening superior vena cava syndrome in neonates. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369070\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16369068\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=93418&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242346\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16255898\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Factor IX concentrations do not change significantly in pregnant women with coagulation disorders and women with factor IX deficiency may be at increased risk of postpartum hemorrhage. Pregnant women should have clotting factors monitored, particularly at 28 and 34 weeks gestation and prior to invasive procedures. Prophylaxis may be needed if factor IX concentrations are &lt;50 units/mL at term and treatment should continue for 3 to 5 days postpartum depending on route of delivery. Because parvovirus infection may cause hydrops fetalis or fetal death, a recombinant product is preferred if prophylaxis or treatment is needed. The neonate may also be at an increased risk of bleeding following delivery and should be tested for the coagulation disorder (Chi 2012; Kadir 2009; Lee 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324140\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Factor IX levels [measure 15 minutes after infusion to verify calculated doses [WFH guidelines (Srivastava 2013)], aPTT, BP, HR, signs of hypersensitivity reactions; screen for factor IX inhibitors if the patient experiences hypersensitivity reaction or when patient is to undergo surgery, if suboptimal response to treatment occurs, if patient is being intensively treated for &gt;5 days within 4 weeks of the last infusion, or at the following intervals [WFH guidelines (Srivastava 2013)]:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Screen for inhibitors every 5 exposure days until 20 exposure days, every 10 exposure days between 21 to 50 exposure days, and at a minimum of twice a year until 150 exposure days is reached.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults (with &gt;150 exposure days apart from a 6 to 12 monthly review): Screen for inhibitors when suboptimal response occurs.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324141\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:0em;display:inline\">Average normal factor IX levels are 50% to 150%; patients with severe hemophilia will have levels &lt;1%, often undetectable. Moderate forms of the disease have levels of 1% to 5% while some mild cases may have 5% to 49% of normal factor IX. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16256038\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Replaces deficient clotting factor IX. Hemophilia B, or Christmas disease, is an X-linked inherited disorder of blood coagulation characterized by insufficient or abnormal synthesis of the clotting protein factor IX. Factor IX is a vitamin K-dependent coagulation factor which is synthesized in the liver. Factor IX is activated by factor XIa in the intrinsic coagulation pathway. Activated factor IX (IXa) in combination with factor VII:C activates factor X to Xa, resulting ultimately in the conversion of prothrombin to thrombin and the formation of a fibrin clot. The infusion of exogenous factor IX to replace the deficiency present in hemophilia B temporarily restores hemostasis.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F242350\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>ss</sub>:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ixinity: 102 to 314 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Rixubis: Children &lt;6 years: ~0.3 L/kg; Children &ge;6 years, Adolescents, and Adults: ~0.2 L/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: BeneFIX: 14 to 28 hours; Rixubis: 23 to 28 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults: Ixinity: 13 to 43 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years, Adolescents, and Adults: Rixubis: ~26 hours</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &gt;15 years and Adults: BeneFIX: 11 to 36 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23324142\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">In absence of inhibitors, 1 unit/kg of factor IX <b><i>recombinant</i></b> will increase plasma factor IX level by 0.7 unit/dL in children &lt;15 years and 0.8 units/dL in adults (WFH guidelines [Srivastava, 2013]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F21663576\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (BeneFIX Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.64</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Ixinity Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">250 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">500 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1000 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1500 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">2000 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3000 unit (Price provided is per AHF Unit): $1.88</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23672676\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Benefiks (UA);</li>\n      <li>Benefix (AR, AT, AU, BE, BG, CN, CO, CY, CZ, DE, DK, EE, ES, FR, GB, GR, HK, HN, HR, HU, IE, IL, IS, IT, JP, KR, LB, LT, LU, MT, NL, NO, PL, QA, RO, RU, SA, SE, SG, SI, SK, TR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and e-ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/3960626/pubmed\" target=\"_blank\" id=\"3960626\">3960626</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batorova A, Martinowitz U. Continuous infusion of coagulation factors. <i>Haemophilia</i>. 2002;8(3):170-177.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/12010406/pubmed\" target=\"_blank\" id=\"12010406\">12010406</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    BeneFIX (coagulation factor IX (recombinant) [prescribing information. Philadelphia, PA: Wyeth Pharmaceuticals Inc: November 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>.1984;33(14):198-199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/6423951/pubmed\" target=\"_blank\" id=\"6423951\">6423951</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chi C, Kadir RA. Inherited bleeding disorders in pregnancy. <i>Best Pract Res Clin Obstet Gynaecol</i>. 2012;26(1):103-117.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/22101176/pubmed\" target=\"_blank\" id=\"22101176\">22101176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chowdary P, Dasani H, Jones JA, et al. Recombinant factor IX (BeneFix) by adjusted continuous infusion: a study of stability, sterility and clinical experience. <i>Haemophilia</i>. 2001;7(2):140-145.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/11260272/pubmed\" target=\"_blank\" id=\"11260272\">11260272</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kadir R, Chi C, Bolton-Maggs P. Pregnancy and rare bleeding disorders. <i>Haemophilia</i>. 2009;15(5):990-1005.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/19298378/pubmed\" target=\"_blank\" id=\"19298378\">19298378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lee CA, Chi C, Pavord SR, et al. The obstetric and gynaecological management of women with inherited bleeding disorders-review with guidelines produced by a Taskforce of UK Haemophilia Centre Doctors' Organization. <i>Haemophilia</i>. 2006;12(4):301-336.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/16834731/pubmed\" target=\"_blank\" id=\"16834731\">16834731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poon MC, Card R. Hemophilia management in transfusion medicine. <i>Transfus Apher Sci</i>. 2012;46(3):299-307.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/22503305/pubmed\" target=\"_blank\" id=\"22503305\">22503305</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rickard KA. Guidelines for therapy and optimal dosages of coagulation factors for treatment of bleeding and surgery in haemophilia. <i>Haemophilia</i>. 1995;1(Suppl 1):8-13.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. <i>Haemophilia</i>. 2013;19(1):e1-47.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/factor-ix-recombinant-human-pediatric-drug-information/abstract-text/22776238/pubmed\" target=\"_blank\" id=\"22776238\">22776238</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 93418 Version 75.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F16255881\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F16255882\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F989980\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F23324145\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F989987\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F242348\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F16255883\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms Considerations\" href=\"#F25573584\" class=\"outlineLink\">Dosage Forms Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F23324139\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F16256024\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F989981\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16255858\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F16256000\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F242351\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F242343\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F27235969\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F16369070\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F16369068\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F242346\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F16255898\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F23324140\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F23324141\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F16256038\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F242350\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F23324142\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F21663576\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F23672676\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/93418|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=factor-ix-recombinant-human-drug-information\" class=\"drug drug_general\">Factor IX, recombinant human: Drug information</a></li><li><a href=\"topic.htm?path=factor-ix-recombinant-human-patient-drug-information\" class=\"drug drug_patient\">Factor IX, recombinant human: Patient drug information</a></li></ul></div></div>","javascript":null}